Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2011 Mar 3

PMID 21364536

Citations 31

Authors

Cynthia C Bartholomae

Anne Arens

Kamaljit S Balaggan

Rafael J Yanez-Munoz

Eugenio Montini

Steven J Howe

Anna Paruzynski

Bernhard Korn

Jens Uwe Appelt

Angus Macneil

Daniela Cesana

Ulrich Abel

Hanno Glimm

Luigi Naldini

Robin R Ali

Adrian J Thrasher

Christof von Kalle

Manfred Schmidt

Affiliations

Soon will be listed here.

Abstract

Lentiviral vectors with self-inactivating (SIN) long terminal repeats (LTRs) are promising for safe and sustained transgene expression in dividing as well as quiescent cells. As genome organization and transcription substantially differs between actively dividing and postmitotic cells in vivo, we hypothesized that genomic vector integration preferences might be distinct between these biological states. We performed integration site (IS) analyses on mouse dividing cells (fibroblasts and hematopoietic progenitor cells (HPCs)) transduced ex vivo and postmitotic cells (eye and brain) transduced in vivo. As expected, integration in dividing cells occurred preferably into gene coding regions. In contrast, postmitotic cells showed a close to random frequency of integration into genes and gene spare long interspersed nuclear elements (LINE). Our studies on the potential mechanisms responsible for the detected differences of lentiviral integration suggest that the lowered expression level of Psip1 reduce the integration frequency in vivo into gene coding regions in postmitotic cells. The motif TGGAA might represent one of the factors for preferred lentiviral integration into mouse and rat Satellite DNA. These observations are highly relevant for the correct assessment of preclinical biosafety studies, indicating that lentiviral vectors are well suited for safe and effective clinical gene transfer into postmitotic tissues.

Citing Articles

Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.

Tawfik M, Chen F, Goldberg J, Sabel B Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(12):1477-1507.

PMID: 36107200 PMC: 9630211. DOI: 10.1007/s00210-022-02287-3.

Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID.

Charrier S, Lagresle-Peyrou C, Poletti V, Rothe M, Cedrone G, Gjata B Mol Ther Methods Clin Dev. 2019; 15:232-245.

PMID: 31720302 PMC: 6838972. DOI: 10.1016/j.omtm.2019.08.014.

In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI Techniques.

Shangaris P, Loukogeorgakis S, Subramaniam S, Flouri C, Jackson L, Wang W Sci Rep. 2019; 9(1):11592.

PMID: 31406195 PMC: 6690943. DOI: 10.1038/s41598-019-48078-4.

Physical principles of retroviral integration in the human genome.

Michieletto D, Lusic M, Marenduzzo D, Orlandini E Nat Commun. 2019; 10(1):575.

PMID: 30718508 PMC: 6362086. DOI: 10.1038/s41467-019-08333-8.

Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease.

Ong T, Pennesi M, Birch D, Lam B, Tsang S Pharm Res. 2019; 36(2):34.

PMID: 30617669 PMC: 6534121. DOI: 10.1007/s11095-018-2564-5.

References

Mooslehner K, Karls U, Harbers K . Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J Virol. 1990; 64(6):3056-8. PMC: 249491. DOI: 10.1128/JVI.64.6.3056-3058.1990. View

Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman M . Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17(11):1919-28. PMC: 2835038. DOI: 10.1038/mt.2009.179. View

Felice B, Cattoglio C, Cittaro D, Testa A, Miccio A, Ferrari G . Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One. 2009; 4(2):e4571. PMC: 2642719. DOI: 10.1371/journal.pone.0004571. View

Marshall H, Ronen K, Berry C, Llano M, Sutherland H, Saenz D . Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One. 2007; 2(12):e1340. PMC: 2129110. DOI: 10.1371/journal.pone.0001340. View

Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I . High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods. 2007; 4(12):1051-7. DOI: 10.1038/nmeth1103. View

Cartier N, Hacein-Bey-Abina S, Bartholomae C, Veres G, Schmidt M, Kutschera I . Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326(5954):818-23. DOI: 10.1126/science.1171242. View

Busschots K, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, Christ F . The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J Biol Chem. 2005; 280(18):17841-7. DOI: 10.1074/jbc.M411681200. View

Barr S, Ciuffi A, Leipzig J, Shinn P, Ecker J, Bushman F . HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. Mol Ther. 2006; 14(2):218-25. DOI: 10.1016/j.ymthe.2006.03.012. View

Zhu L, Chou S, Reid B . The structure of a novel DNA duplex formed by human centromere d(TGGAA) repeats with possible implications for chromosome attachment during mitosis. J Mol Biol. 1995; 254(4):623-37. DOI: 10.1006/jmbi.1995.0643. View

10.

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F . Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010; 467(7313):318-22. PMC: 3355472. DOI: 10.1038/nature09328. View

11.

Paruzynski A, Arens A, Gabriel R, Bartholomae C, Scholz S, Wang W . Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc. 2010; 5(8):1379-95. DOI: 10.1038/nprot.2010.87. View

12.

Blomer U, Naldini L, Kafri T, Trono D, Verma I, Gage F . Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997; 71(9):6641-9. PMC: 191942. DOI: 10.1128/JVI.71.9.6641-6649.1997. View

13.

Yanez-Munoz R, Balaggan K, Macneil A, Howe S, Schmidt M, Smith A . Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006; 12(3):348-53. DOI: 10.1038/nm1365. View

14.

Scherdin U, Rhodes K, Breindl M . Transcriptionally active genome regions are preferred targets for retrovirus integration. J Virol. 1990; 64(2):907-12. PMC: 249188. DOI: 10.1128/JVI.64.2.907-912.1990. View

15.

Allen M, Jeffreys A, Surani M, Barton S, Norris M, Collick A . Tandemly repeated transgenes of the human minisatellite MS32 (D1S8), with novel mouse gamma satellite integration. Nucleic Acids Res. 1994; 22(15):2976-81. PMC: 310264. DOI: 10.1093/nar/22.15.2976. View

16.

Mitchell R, Beitzel B, Schroder A, Shinn P, Chen H, Berry C . Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004; 2(8):E234. PMC: 509299. DOI: 10.1371/journal.pbio.0020234. View

17.

Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M . LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol. 2004; 78(17):9524-37. PMC: 506940. DOI: 10.1128/JVI.78.17.9524-9537.2004. View

18.

Bushman F . Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell. 2003; 115(2):135-8. DOI: 10.1016/s0092-8674(03)00760-8. View

19.

Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P . A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med. 2005; 11(12):1287-9. DOI: 10.1038/nm1329. View

20.

Schroder A, Shinn P, Chen H, Berry C, Ecker J, Bushman F . HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002; 110(4):521-9. DOI: 10.1016/s0092-8674(02)00864-4. View